FDA Approves Novel Targeted Therapy for Rare Blood Cancer

Published Date: 29 May 2026

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Read Full News

Latest News

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

Latest News

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Women with breast cancer show interest in self-injecting their medication.

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

News All Time

Are Microplastics Feeding Cancer Risk?

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Does Maintenance Therapy Extend Life in mCRC?

Maintenance therapy is linked to longer overall survival after first-line bevacizumab-based combination chemotherapy in patients with metastatic colorectal cancer, a study finds.

Preschoolers With Cancer Have Poor Motor Skills

Preschool children newly diagnosed with cancer exhibit significant motor impairments, reduced mobility, and weak grip strength at diagnosis, study shows.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Fixed-Duration Combo Shows Promise for Relapsed MCL

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

US Cancer Trials Heavily Favor Single Drugs Over Care Issues

Industry trials focus on single drugs, while publicly funded trials often look at broader cancer care. It’s a ‘complementary’ approach, but pharma enrolls over 90% of patients.

Ruxolitinib Reduces Acute GVHD in Transplant Patients

A phase 3 trial evaluates a low-dose ruxolitinib-based regimen for graft-vs-host disease prophylaxis among patients undergoing haploidentical hematopoietic stem-cell transplantation.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

3.

Cancer care crowdfunding increasingly common, but rarely successful

4.

Immunotherapy Is As Safe As Other Cancer Treatments During Pregnancy.

5.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

1.

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis

2.

Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options

3.

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders

4.

Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked

5.

AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

3.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

5.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

Latest News

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

Talc Powder Not Linked to Lung Cancer in Women

Saturated Fat Tied to Worse Survival After Prostate Cancer

Medication Self-Injection Embraced by Breast Cancer Patients

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

Todays Updates

Sevabertinib Approved for First-Line Mutated NSCLC

Latest News

News All Time

Are Microplastics Feeding Cancer Risk?

Does Maintenance Therapy Extend Life in mCRC?

Preschoolers With Cancer Have Poor Motor Skills

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

Fixed-Duration Combo Shows Promise for Relapsed MCL

US Cancer Trials Heavily Favor Single Drugs Over Care Issues

Ruxolitinib Reduces Acute GVHD in Transplant Patients

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

How Much of a Cancer Drug Is Too Much?

Belgian Algorithm Reshapes Endometrial Cancer Care

NPM1-Mutated AML: Not All Treatments Are Equal

Transgender Individuals Prefer HPV Self-Swabs

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

FDA Approves Iberdomide Combo for Multiple Myeloma

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Wide Variation Seen in Lung Screening False-Positive Rates

Recommended News For You

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care

Researchers study effects of cannabis on sedation, cancer treatment symptoms

Gene therapies for BCG-unresponsive bladder cancer have high response rates.